https://www.businesswire.com/news/home/20250311572254/en/Edgewise-Therapeutics-to-Present-on-Sevasemten-for-the-Treatment-of-Becker-Muscular-Dystrophy-at-the-2025-MDA-Clinical-and-Scientific-Conference
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at...
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevase...